GE Healthcare recently announced its launch of Clariscan (gadoteric acid), a gadolinium-based contrast agent (GBCA) designed to support effective visualization of abnormalities in the brain, spine and associated tissues. The contrast agent will be provided alongside GE Healthcare’s support services.
“Gadolinium-based agents are known to be a gold-standard detection tool in MR imaging, offering improved contrast between normal and pathological tissue to enable rapid detection of abnormalities. It is important that radiologists are able to make a contrast media selection dependent on the needs of individual patients,” said Emmanuel Ligner, general manager of core imaging for GE Healthcare Life Sciences, in a statement.
In the past decade alone, demand for contrast media has significantly increased due to rapid procedural advancements in MRI. Clariscan will be available in various doses in vials and pre-filled syringes. It will be introduced to European countries throughout 2017.
“We are pleased to add Clariscan to the family of GE contrast media and imaging products alongside our existing linear agent for MRI, Omniscan, which has been used in routine diagnostic practice for over 25 years with more than 80 million administrations. We believe macrocyclic Clariscan, manufactured using a proprietary GE process, extends choice for radiology professionals, backed by the well-established quality, reliability and surrounding services GE customers have come to expect," said Ligner.